Taking lenient stance, NICE backs neuroblastoma drug
Body makes special case due to rarity of the disease
X
Taking lenient stance, NICE backs neuroblastoma drug
https://pharmaphorum.com/news/taking-lenient-stance-nice-backs-neuroblastoma-drug/
neuroblastoma
EUSA Pharma approval fills gap in neuroblastoma market
Company can move in after United Therapeutics withdrew its product Unituxin
Brain cancer drug too expensive, says NICE
Unituxin too costly for use in children, NICE says.